Trials
4 active
5 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NXT007 will be administered subcutaneously (SC) using an integrated drug-device combination product.”In the company’s words, NCT07416526 on ClinicalTrials.gov
- Tested for
- Hemophilia A (4 trials)
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without FVIII inhibitors. The study will include people aged ≥12 years old who have been on FVIII prophylaxis treatment prior to study entry.”In the company’s words, NCT07416526 on ClinicalTrials.gov
- Other names
- RO7589655 · Zemocimig · RG6512
Other drugs for Hemophilia A
- GS1191-0445Gritgen Therapeutics Co., Ltd. · Phase 3
- FRSW107Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Phase 3
- SR604Shanghai RAAS Blood Products Co., Ltd. · Phase 3
- KN057Suzhou Alphamab Co., Ltd. · Phase 3
- DenecimigNovo Nordisk · Phase 3
- MarstacimabPfizer · Phase 3
Coming up4
- 23 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 29 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 11 Dec 2033Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07838194
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 23 Sep 2027 | A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | |
| Phase 3Recruiting | 29 Feb 2028 | A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A | |
| Phase 3Recruiting | 30 Sep 2028 | Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children | |
| Phase 1/2Recruiting | 11 Dec 2033 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A | |
| Phase 1Completed | 22 Dec 2024 | A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026